Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Hepatocellular 18Colorectal Neoplasms 17Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 9Advanced Solid Tumor 9Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Esophageal Neoplasms 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

tislelizumab 1S 1 (combination) 1Paclitaxel 1Hyperthermic Intraperitoneal Chemotherapy 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Cancer Peritoneal Metastases × tislelizumab × 1 year × Clear all
NCT07304258 2025-12-26

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Hebei Medical University

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Gastric Cancer Peritoneal Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡